Hi there, we see you're using OS, why not try our app?
Download
Skip to main content

Contacts and partners


We are working with colleagues in the wider NHS, regulatory and industry bodies as well as academic partners to explore COVID-19 research and trials.

NHSBT media

email: pressoffice@nhsbt.nhs.uk

Phone: 01923 367 600 (24 hours a day)

Our programme partners

Government departments, agencies and public bodies

Department of Health & Social Care

Public Health England

NHS Digital

National Institute for Health Research

Universities and departments

University of Cambridge

King's College London

University of Oxford

Radcliffe Department of Medicine

Nuffield Department of Medicine

Nuffield Department of Surgical Sciences

Wellcome Trust Centre for Human Genetics

Hospitals

Guy's and St Thomas' NHS Foundation Trust

Addenbrooke's Hospital

John Radcliffe Hospital

Blood donation services

Scottish National Blood Transfusion Service

Welsh Blood Service

Interested parties

Royal College of Pathologists

British Society of Haematology

"This ground-breaking REMAP-CAP trial, conducted by NHSBT, will test whether convalescent plasma treatment can save lives and shorten intensive care unit stays."

Professor David Menon

Emeritus Senior Investigator, National Institute for Health Research

"NHS Blood and Transplant is now collecting convalescent plasma for use in a randomised clinical trial as a potential treatment for COVID-19. We are investigating whether this plasma can improve survival and reduce ventilation and intensive care unit stay in COVID-19 patients. This is an exciting development as there is no proven treatment for COVID-19."

Professor David Roberts

Associate Medical Director, NHS Blood and Transplant

"The REMAP-CAP trial has been specifically designed to provide answers about the best treatment options for the most seriously ill with COVID-19. It is fully adaptive, meaning that new treatments can be added as we learn more, the sample size isn’t fixed and it keeps recruiting until it finds that a treatment is better, worse, or the same as another."

Professor Anthony Gordon

NIHR Research Professor and Chief Investigator for REMAP-CAP